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Editorial
Early  oral  cancer  management  during  the  COVID-19  period
This  COVID-19  pandemic  has raised  urgent  challenges  in  the
provision  of healthcare. To  help  guide  clinicians  during this
time,  several  national  and international  articles have  been
published,  including  guidelines  from  professional  groups,
that relate  to the  management  of head  and  neck cancer
(HNC).1–5 HNC-related surgery  has  been  affected  by  delays
or cancellations,  which  have  been  influenced  in  part  by  the
capacity of intensive  care  units  (ICU).3 It was necessary  to
introduce  changes in  treatment  rapidly, and these might  have
far-reaching consequences  for the  future  provision  of clinical
care.
Immediate  consequences  of  the  pandemic  have been the
anxiety and  uncertainty  that  have  been  felt  by patients,  car-
ers, clinicians,  and  hospitals.  There  has been a  need to  reduce
face-to-face contact,  and  this  has  had an  impact  not only  on
surgery  itself,  but  also  on  the way  outpatient  consultations
take place.  In  the past,  the priorities  for  HNC  treatment  have
been survival  and cure.  Functional  deficits  and health-related
quality of  life (HRQoL), although important,  have  been sec-
ondary to treatments  that  offer the best  chance  of  a cure.6
During  the  pandemic,  however,  a new  concern  has  arisen
amongst  everyone  involved  - that  of  the risk  from COVID-
19.7
It  will  be of value to  reflect  on  the role  of  this  risk  in
the shaping  of  oral  cancer  care,  especially  in  patients  with
early-stage disease  when  disease-specific  survival,  postoper-
ative dysfunction,  and HRQoL  are relatively  good.  There  are
aspects  of disease  management  for  which  the lack  of  robust
evidence results  in uncertainty  as to  which  approach  is best,
and equipoise  is present.  A patient’s preference has an  impor-
tant role, with  all  those affected  having  to  balance  the  risk
from COVID-19  against the outcomes  of their  oral  cancer.
This will  shape  future  protocols.
The  standard  of  care  for  patients  with  oral  squamous  cell
carcinoma (OSCC)  is primary  surgical  resection  with  or  with-
out postoperative  adjuvant  therapy8 and,  depending  on the
nature  of the  defect, free-tissue  transfer  may be  necessary.
For the present  (and  at least  in  the  medium  term)  during
the treatment  planning stage,  clinicians  will  have  to  consider
survival, morbidity,  the  need for tracheostomy  (a  high-risk
procedure  for  the transmission  of COVID-19),  and available
resources, including  the  number  of hospital  admissions  and
hospital  stay. Patients who  have  free-flap  reconstruction  stay
longer in  hospital.  It  can be  argued  - taking  into  account  the
results of  the  COVIDSurg  study2 - that there  is a measurable
risk of  COVID-19  transmission  during  the hospital  stay, and a
shorter stay  with  reduced  healthcare  contacts  might  reduce  it.
Free-flap reconstruction  can  have  distinct  advantages  in terms
of  recovery.  In  addition  to  better  function  and a  reduced  risk
of  fistula  and other complications,  it can -  by  virtue  of  cover-
ing the resection defect  - result  in  a  rapid recovery,  especially
if there  is no  need  for  a tracheostomy.
Neck metastasis  in  OSCC is a major  prognostic vari-
able in overall  survival.  While  there  is a general  consensus
that patients  with  T3  and T4 N0  primary  OSCC or
clinically-evident nodal  metastases should  have  neck  dis-
section,  little  consensus  exists  for patients  with  early-stage
OSCC (T1N0/T2N0)  and clinically  and  radiologically  node-
negative necks.9 Sentinel  node  biopsy (SNB)  is capable  of
detecting occult  metastases  in  early  oral  cancer  and is a safe
technique  for  staging  the clinically  N0 neck,10 although  a pro-
portion of  patients  will  require  readmission  for  a  completion
neck dissection (CND).  The  SEND  trial  concluded that  for
early oral  cancer,  elective  neck dissection  (END) resulted  in
better  disease-free  survival  than  wait  and watch,11 and can be
completed during one hospital  admission. This  is in  contrast
to those  who  require  completion  neck dissection  following
SNB.
Patients with early oral  cancer are a  heterogeneous  group
and this  is often poorly  reflected  in  the literature.  Uncertainty
arises  because  patients  with  larger  tumours  (when it has been
decided  that  a free  flap  is not required)  are likely to  have
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a survival  advantage with  surgical  staging  of  the neck, and
this can  be  an  END or  SNB.  On the  other hand,  thin  tumours
might have a lower  risk  of occult metastasis and  END may  not
be necessary,  although  sentinel  lymph  node  biopsy  (SLNB)
might be preferable  to  wait and watch.  There  is always  a
risk of ipsilateral  or  contralateral  failure  irrespective  of  which
approach  is  used. Rates  are  low  and SLNB  has an  advantage,
especially when  tumours encroach on  the  midline  or  have
unexpected patterns  of  drainage.
The concern  about  the added  morbidity  of  CND compared
with END  is frequently  raised.  This  is an  important  consid-
eration and  further  investigation is warranted.  In  the  current
climate, SLNB  has  the  disadvantage  that  when CND is indi-
cated, two  episodes  of  isolation,  testing,  and shielding  may
be  required before  the  completion  of  surgery. These  patient
pathways differ  from  hospital  to  hospital  and the  impact  of
this  will  change  over  time.  While  the  node-positive  rates  in  the
SEND  trial for T1 and T2  cancers  were  19.1% and 36.7%,
respectively (with other  trials  of  END  and SLNB showing
similar figures11,12),  it may  be  that  advances in  preoperative
imaging  could allow  more node-positive  patients  to be  identi-
fied during  staging.  Also, in  the  future  it might  be  possible  to
improve the  early detection  of  lymph  node  metastasis  during
follow up in  the  wait and  watch  group.
In early  oral  cancer  it is  difficult  to  make  valid  com-
parisons, and  interpretation  is fraught  with  difficulty  in  the
absence  of  randomised  trials.  HRQoL  is  better  in  those who
have laser  resection  with END  than  it is in  those who  have
free flaps.  However,  this  is likely  to  be  because  the tumours
are different  –  that  is,  much  larger in  the free  flap  group  -
and of course  the outcome  is  worse in those who also have
postoperative radiotherapy  (PORT).
The patient’s  perspective  needs  to  be  considered for  every
treatment option.  Even  well-informed  patients  can find  it dif-
ficult to  understand,  in  any  meaningful  way, the  differences
between SLNB,  END,  and watch and wait,  and for  most,
the surgeon’s  preference  and influence  is the  most  important
factor in decision  making.
At  this  moment in  time,  for patients  with  clinically  and
radiographically staged  N0 neck  oral  cancer,  there is a  ratio-
nale for the simplification  of  surgery  with primary  resection,
the avoidance  of tracheostomy,  and careful  consideration  of
the  optimal  treatment  of  the neck.  There  is,  however, a  trade-
off based  on uncertainty.  Simplifying surgical management
may shorten  the  hospital  stay, reduce  the burden  on  services,
and enable  the backlog  of  cases to  be treated  quickly,  without
having a detrimental  effect  on  crude  survival  or disease-
specific survival.  Not  only  will  reduced  surgical interventions
result in  shortened  waiting times  for cancer  patients,  they
might  also free  up  surgical  lists  when capacity  is limited,  for
important but  less  urgent  cases.  This  trade-off  would  prob-
ably be  something  that  would  resonate  with  patients,  given
the unprecedented  situation.
As COVID-19  will  have  an  impact  on  surgical  practice
for the  foreseeable  future, any  changes  in practice  need  to  be
carefully  audited.  Balancing  optimal  cancer  treatments  with
the  risk  of  COVID-19  is an  inexact  science based  on incom-
plete evidence  and an  evolving  knowledge  base. The risk will
vary with time  and location  as  the  prevalence of  COVID-19
changes. Individual  multidisciplinary  teams  may  find  at times
that national  guidance  does  not reflect  the situation  in  their
institution, and approaches  to  treatment  need  to  be  adaptable
to  account  for  this.
Finally,  every cancer  patient  requires  careful  clinical  fol-
low up  to  check  for treatment  failure, to  aid rehabilitation,  and
identify  unmet  needs.13 The  COVID-19  crisis has resulted  in
reduced  patient contact,  and social  distancing.  Patient  follow-
up  models  will  evolve,  but  patients  still  value the chance
to discuss  their  concerns  and  seek  reassurance. Technology
will help  shape  the way consultations  take place,  but  some
patients will  inevitably  benefit  from  a face-to-face  appoint-
ment. Although  the  prognosis  for  early oral  cancer  is  good,
one of their  main  concerns will  be  about  recurrence,  and
the physical examination  is very  reassuring.  Preoperative
preparation  and  follow-up  prompt  lists  have been  developed
and are  in  use  in  the  UK.14,15 This  model  of  care,  resulting
as  a  consequence  of  the  COVID-19  pandemic,  could sup-
port the  foundation  of  a  new  more virtually based  follow-up
approach.
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